



Ministry of Science and Higher Education
Republic of Poland

Co-financed by the project of Minister of Science and Higher Education "Industry Contact Points for the Horizon Europe Research and Innovation Framework Programme"



Industry
Contact
Point
Medical
Technologies
and Health



Industry
Contact
Point
Digital
Transformation



Industry
Contact
Point
Industry 4.0

LOWER SILESIA



DOLNY
ŚLĄSK

STUDY VISIT & MATCHMAKING

Digital hospital

Please wait...



Independent Public Health Care Institution – ***Dr Alfred Sokołowski Specialist Hospital*** in Walbrzych, Poland

- Contact person name: Prof. Aleksandra Butrym
- **Contact:**
- aleksandra.butrym@gmail.com
- Institution website: <https://www.zdrowie.walbrzych.pl>



Dr Alfred Sokołowski Specialist Hospital – Walbrzych, Poland



- **Comprehensive care** - hematology, oncology, oncological surgery, cardiology, and more.
- **Strong R&D activity** - projects worth over PLN 100 million (ABM, National Recovery Plan).
- **OncoCRSC** - coordination of commercial and non-commercial clinical trials.
- **Molecular Biology Laboratory** - NGS, PCR, genomic profiling.
- **Interdisciplinary team** - physicians, nurses, pharmacists, geneticists, bioinformaticians, laboratory diagnosticians, coordinators, project managers, biostatisticians.
- **Academic partnerships** - universities, research institutes, industry, professional associations.
- **Medical University affiliation** - 5 clinical departments opened in 2025, growing to 15.



Dr Alfred Sokołowski Specialist Hospital – Walbrzych, Poland



AVO-CLL trial: A multicentre, randomised, open-label phase 3 study comparing the efficacy and safety of acalabrutinib in combination with obinutuzumab versus venetoclax in combination with obinutuzumab in first-line treatment of newly diagnosed chronic lymphocytic leukaemia.

- **Design:** Multicentre, randomised, open-label phase 3 trial
- **Objective:** Compare efficacy and safety of:
 - *Acalabrutinib + Obinutuzumab vs Venetoclax + Obinutuzumab*
- **Indication:** First-line treatment of newly diagnosed chronic lymphocytic leukaemia (CLL)
- **Planned enrolment:** 72 patients in leading haematology centres across Poland
- **Our role:** Sponsor & Coordinating Centre
 - Protocol design
 - Oversight of all participating sites
 - Quality monitoring & GCP compliance
- **Patient benefit:** Access to innovative targeted therapies not yet widely available in public healthcare
- **Potential impact:** Evidence to inform future treatment standards in CLL in Poland and globally



Dr Alfred Sokołowski Specialist Hospital – Walbrzych, Poland



Single-center, single-arm research experiment to evaluate the effectiveness of laser ablation in the treatment of early breast cancers with histologically confirmed T1 breast cancer.

- **Design:** Single-centre, single-arm interventional research experiment
- **Objective:** Evaluate the effectiveness and safety of ultrasound-guided laser ablation for T1 breast cancers (≤ 20 mm)
- **Planned enrolment:** 100 patients with histologically confirmed early-stage breast cancer
- **Procedure:**
 - Local anaesthesia with hydrodissection
 - Ultrasound-guided 21G needle insertion
 - Laser ablation (3W power, 5–10 min)
 - Marker placement → followed by standard breast-conserving surgery (BCS)
- **Primary endpoint:** Pathological complete response (pCR) rate
- **Secondary endpoints:** Safety profile, adverse events, quality of life, cosmetic outcome
- **Potential impact:** Less invasive alternative to traditional surgery, shorter recovery, fewer complications, better quality of life



Our research support asset



Oncology Clinical Research Support Center - Development & Molecular Biology Laboratory

- **Scope:** Expansion of research infrastructure & creation of a state-of-the-art Molecular Biology Laboratory
- **Capabilities:** Genomic profiling (NGS, PCR), single-cell sequencing, biomarker research, bioinformatics
- **Objectives:** Strengthen translational oncology, accelerate personalised therapies, boost trial participation
- **Resources:** Modern molecular diagnostics equipment, dedicated lab spaces, multidisciplinary expert team
- **Impact:** Faster patient access to advanced diagnostics, stronger position in European research networks, Improved research quality and competitiveness in Horizon Europe collaborations



Calls of interest



- **HORIZON-HLTH-2027-01-CARE-02** – Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications
Our scope: AI-based clinical decision-support tool flagging polypharmacy/ADR risk in elderly oncology & hematology patients, using real-world data from our hematology ward and EHDS-aligned datasets.
- **HORIZON-HLTH-2027-02-TOOL-01-two-stage** – Predictive biomarkers of disease progression & treatment response using AI for chronic non-communicable diseases
Our scope: Clinical site providing paired FFPE biopsies, MRD flow cytometry & longitudinal PRO data (from AVO-CLL) to train/validate AI biomarker models for CLL progression and treatment response.
- **HORIZON-HLTH-2027-03-TOOL-04** – Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis
Our scope: Clinical validation partner contributing hematology/oncology patient pathway data to build & test a virtual-twin module for treatment-sequencing decisions in CLL/MDS/MM.
- **HORIZON-HLTH-2027-02-DISEASE-01-two-stage** – Innovative healthcare interventions for non-communicable diseases
Our scope: Clinical trial site (building on AVO-CLL infrastructure: PI experience, GCP-compliant sites, MRD & biobank pipeline) for an interventional study testing a novel treatment-sequencing approach in CLL or MDS.

Our R&D potential



HE projects require demonstrated capacity to deliver research & development tasks. Our own resources:

- **Own R&D unit:** OnkoCWBK – Oncological Clinical Research Support Centre, running 25+ international sponsored & non-commercial clinical trials, with dedicated study coordinators, regulatory/GCP support and quality monitoring.
- **Scientific & clinical staff:** Multidisciplinary team of hematology/oncology physicians, study coordinators and biostatisticians; PI experience on an investigator-initiated Phase III RCT (AVO-CLL, EU-CT, ABM-funded).
- **Equipment & infrastructure:** Newly opened, KPO/ABM-funded Molecular Biology Laboratory (NGS, PCR, single-cell sequencing) with ERIC certification for TP53 NGS assessment; MRD assessment by flow cytometry.
- **Own data & biological material (IP):** Paired FFPE trephine biopsy biobank, longitudinal MRD & PRO data (EORTC QLQ-C30, EQ-5D-5L, FACIT-Fatigue) generated within AVO-CLL, available for future translational & AI research.
- **Partnership network:** University affiliation (Wroclaw Medical University), academic & industry partnerships, and access to broader expertise via collaborating research institutes when own capacity needs to be complemented.





Ministry of Science and Higher Education
Republic of Poland

Co-financed by the project of Minister of Science and Higher Education "Industry Contact Points for the Horizon Europe Research and Innovation Framework Programme"



Industry
Contact
Point
Medical
Technologies
and Health



Industry
Contact
Point
Digital
Transformation



Industry
Contact
Point
Industry 4.0

LOWER
SILESIA



DOLNY
ŚLĄSK

Thank you

Thank you!

Contact: aleksandra.butrym@gmail.com

Digital hospital